Key result
Genomic and proteomic advances reveal molecular pathways linking HF with comorbidities to identify personalized therapies.
Why the study?
Recent advances in genomics and proteomics have enhanced understanding of molecular mechanisms linking comorbidities and heart failure, highlighting the need to review these pathways to inform novel and personalized therapies.
Understanding the molecular alterations shared between heart failure and its comorbidities provides a foundation for developing targeted, precision medicine strategies.
May guide precision HF therapies targeting comorbidities; leaves open prospective validation of molecular targets.
Recent advances in genomics and proteomics have helped in understanding the molecular mechanisms and pathways of comorbidities and heart failure. In this narrative review, we reviewed molecular alterations in common comorbidities associated with heart failure such as obesity, diabetes mellitus, systemic hypertension, pulmonary hypertension, coronary artery disease, hypercholesteremia and lipoprotein abnormalities, chronic kidney disease, and atrial fibrillation. We searched the electronic databases, PubMed, Ovid, EMBASE, Google Scholar, CINAHL, and PhysioNet for articles without time restriction. Although the association between comorbidities and heart failure is already well established, recent studies have explored the molecular pathways in much detail. These molecular pathways demonstrate how novels drugs for heart failure works with respect to the pathways associated with comorbidities. Understanding the altered molecular milieu in heart failure and associated comorbidities could help to develop newer medications and targeted therapies that incorporate these molecular alterations as well as key molecular variations across individuals to improve therapeutic outcomes. The molecular alterations described in this study could be targeted for novel and personalized therapeutic approaches in the future. This knowledge is also critical for developing precision medicine strategies to improve the outcomes for patients living with these conditions.
No takes yet. Share an insight, caveat, or question.
Appunni et al. (2024) conducted a review in Heart failure and associated comorbidities. Recent advances in genomics and proteomics have elucidated the molecular mechanisms and pathways linking heart failure with common comorbidities, offering potential targets for personalized therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: